Vijaya Diagnostic Centre growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+19.5%+24.4%+19.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+23.3%+23.7%+21.4%
+21.0%+23.6%+36.2%
+20.3%+20.2%+40.4%
+20.5%+20.1%+40.2%
+18.3%+29.6%+15.2%
+19.8%+21.1%+20.7%
+20.5%+22.5%+11.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VIJAYA₹1,400.00

Vijaya Diagnostic Centre Ltd.

· Pharma & Health
₹ CrorePeersTHYROCAREMETROPOLISLALPATHLABRAINBOWPOLYMEDPFIZERONESOURCEKIMSMcap ₹14,406 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+19.3+24.4+19.5—
EBITDA Growth—+21.4+23.7+23.3—
EBIT Growth—+36.2+23.6+21.0—
Net Income Growth—+40.4+20.2+20.3—
EPS Growth—+40.2+20.1+20.5—
Total Assets Growth—+15.2+29.6+18.3—
Total Equity Growth—+20.7+21.1+19.8—
Cash from Operations Growth—+11.4+22.5+20.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.